Nicholas Investment Partners’s Pacira BioSciences PCRX Stock Holding History

Nicholas Investment Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-35,325	Closed	-$1.87M	–	324
2016 Q1	$1.87M	Sell	35,325 -15,525	-31%	-$908K	0.14%	242
2015 Q4	$3.9M	Buy	50,850 +15,054	+42%	+$852K	0.27%	160
2015 Q3	$1.47M	Buy	35,796 +9,229	+35%	+$565K	0.11%	269
2015 Q2	$1.88M	Buy	26,567 +5,611	+27%	+$442K	0.12%	268
2015 Q1	$1.86M	Sell	20,956 -6,847	-25%	-$695K	0.12%	265
2014 Q4	$2.46M	Buy	27,803 +8,544	+44%	+$808K	0.15%	223
2014 Q3	$1.87M	Buy	+19,259	New	+$1.87M	0.12%	244

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nicholas Investment Partners's PCRX Position: Q2 2016 in Review

Nicholas Investment Partners sold out of Pacira BioSciences (PCRX) in Q2 2016, closing a stake of 35,325 shares — an estimated $1.87M sold.

Nicholas Investment Partners first reported a position in PCRX in Q3 2014 and held it in 7 quarters. The position peaked at $3.9M in Q4 2015. 183 funds tracked by Wall St. Rank hold PCRX as of Q2 2016.

Nicholas Investment Partners reported no remaining Pacira BioSciences position as of Q2 2016 after selling out during the quarter.
Nicholas Investment Partners sold 35,325 Pacira BioSciences shares in Q2 2016, an estimated $1.87M.
Nicholas Investment Partners first reported a position in Pacira BioSciences in Q3 2014 and held it in 7 quarters.
Nicholas Investment Partners's Pacira BioSciences position peaked at $3.9M in Q4 2015.
183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2016.

Based on Nicholas Investment Partners's 13F filing for Q2 2016, filed 12 Aug 2016.